Individualised incretin-based treatment for type 2 diabetes

被引：10

作者：

Nauck, Michael A. ^{[1
]}

Meier, Juris J. ^{[2
]}

机构：

[1] Diabet Zentrum Bad Lauterberg, D-37431 Bad Lauterberg Im Harz, Germany

[2] Klinikum Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, Bochum, Germany

来源：

LANCET | 2010年 / 376卷 / 9739期

关键词：

GLUCAGON-LIKE PEPTIDE-1; OPEN-LABEL; GLYCEMIC CONTROL; INHIBITORS; EXENATIDE; METFORMIN; TRIAL;

D O I：

10.1016/S0140-6736(10)60998-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：393 / 394

页数：2

共 12 条

[1] Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial [J].

Bergenstal, Richard M. ;

Wysham, Carol ;

MacConell, Leigh ;

Malloy, Jaret ;

Walsh, Brandon ;

Yan, Ping ;

Wilhelm, Ken ;

Malone, Jim ;

Porter, Lisa E. .

LANCET, 2010, 376 (9739) :431-439

[2] Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial [J].

Diamant, Michaela ;

Van Gaal, Luc ;

Stranks, Stephen ;

Northrup, Justin ;

Cao, Dachuang ;

Taylor, Kristin ;

Trautmann, Michael .

LANCET, 2010, 375 (9733) :2234-2243

[3] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].

Drucker, Daniel J. ;

Buse, John B. ;

Taylor, Kristin ;

Kendall, David M. ;

Trautmann, Michael ;

Zhuang, Dangliang ;

Porter, Lisa .

LANCET, 2008, 372 (9645) :1240-1250

[4] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[5] Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects [J].

Elbrond, B ;

Jakobsen, S ;

Larsen, S ;

Agerso, H ;

Jensen, LB ;

Rolan, P ;

Sturis, J ;

Hatorp, V ;

Zdravkovic, M .

DIABETES CARE, 2002, 25 (08) :1398-1404

[6] Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? [J].

Nauck, M. ;

Smith, U. .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) :513-523

[7] Glucagon-like peptide 1 and its derivatives in the treatment of diabetes [J].

Nauck, MA ;

Meier, JJ .

REGULATORY PEPTIDES, 2005, 128 (02) :135-148

[8] Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind placebo-controlled study [J].

Nauck, Michael A. ;

Ratner, Robert E. ;

Kapitza, Christoph ;

Berria, Rachele ;

Boldrin, Mark ;

Balena, Raffaella .

DIABETES CARE, 2009, 32 (07) :1237-1243

[9] Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial [J].

Pratley, Richard E. ;

Nauck, Michael ;

Bailey, Timothy ;

Montanya, Eduard ;

Cuddihy, Robert ;

Filetti, Sebastiano ;

Thomsen, Anne Bloch ;

Sondergaard, Rie Elvang ;

Davies, Melanie .

LANCET, 2010, 375 (9724) :1447-1456

[10] Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM [J].

Rachman, J ;

Gribble, FM ;

Barrow, BA ;

Levy, JC ;

Buchanan, KD ;

Turner, RC .

DIABETES, 1996, 45 (11) :1524-1530

← 1 2 →